Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 9, 2017, Pages 1587-1592

  Abraham, Allistair ^a   Cluster, Andrew ^b   Jacobsohn, David ^a   Delgado, David ^c   Hulbert, Monica L ^b   Kukadiya, Divyesh ^a   Murray, Lisa ^b   Shenoy, Shalini ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Sickle cell disease; Stem cell transplant; Unrelated cord blood

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DEFIBROTIDE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; MELPHALAN; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TACROLIMUS; THIOTEPA; MYCOPHENOLIC ACID; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS INFECTION; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; ENGRAFTMENT; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER VENOOCCLUSIVE DISEASE; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POST TREATMENT SURVIVAL; REDUCED INTENSITY CONDITIONING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINITIS; SICKLE CELL ANEMIA; UMBILICAL CORD BLOOD; UNRELATED CORD BLOOD TRANSPLANTATION; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; IMMUNOLOGY; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

ALEMTUZUMAB; ANEMIA, SICKLE CELL; CALCINEURIN INHIBITORS; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; HYDROXYUREA; MALE; MELPHALAN; MYCOPHENOLIC ACID; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; VIDARABINE;

EID: 85023755721     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2017.05.027     Document Type: Article

References (35)

1. Gluckman, E., Cappelli, B., Bernaudin, F., et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 129 (2017), 1548–1556.
2. Walters, M.C., De Castro, L.M., Sullivan, K.M., et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 22 (2016), 207–211.
3. Bernaudin, F., Socie, G., Kuentz, M., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110 (2007), 2749–2756.
4. Mentzer, W.C., Heller, S., Pearle, P.R., Hackney, E., Vichinsky, E., Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 16 (1994), 27–29.
5. Justus, D., Perez-Albuerne, E., Dioguardi, J., Jacobsohn, D., Abraham, A., Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease. Pediatr Blood Cancer 62 (2015), 1285–1287.
6. Adamkiewicz, T.V., Boyer, M.W., Bray, R., Haight, A., Yeager, A.M., Identification of unrelated cord blood units for hematopoietic stem cell transplantation in children with sickle cell disease. J Pediatr Hematol Oncol 28 (2006), 29–32.
7. Parikh, S.H., Mendizabal, A., Benjamin, C.L., et al. A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with non-malignant diseases. Biol Blood Marrow Transplant 20 (2014), 326–336.
8. Pai, S.Y., Logan, B.R., Griffith, L.M., et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 371 (2014), 434–446.
9. Inamoto, Y., Kimura, F., Kanda, J., et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica 101 (2016), 1592–1602.
10. Kamani, N.R., Walters, M.C., Carter, S., et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 18 (2012), 1265–1272.
11. Ruggeri, A., Eapen, M., Scaravadou, A., et al. Umbilical cord blood transplantation for children with thalassemia and sickle. Biol Blood Marrow Transplant 17 (2011), 1375–1382.
12. Adamkiewicz, T.V., Szabolcs, P., Haight, A., et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 11 (2007), 641–644.
13. Fitzhugh, C.D., Abraham, A.A., Tisdale, J.F., Hsieh, M.M., Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematol Oncol Clin North Am 28 (2014), 1171–1185.
14. Jagasia, M.H., Greinix, H.T., Arora, M., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I, The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21 (2015), 389–401 e1.
15. Przepiorka, D., Weisdorf, D., Martin, P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995), 825–828.
16. Gaziev, J., Isgrò, A., Sodani, P., et al. Optimal outcomes in young class 3 patients with thalassemia undergoing HLA-identical sibling bone marrow transplantation. Transplantation 100 (2016), 925–932.
17. Walters, M.C., Storb, R., Patience, M., et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 95 (2000), 1918–1924.
18. Eggleston, B., Patience, M., Edwards, S., et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol 136 (2007), 673–676.
19. Madden, L.M., Hayashi, R.J., Chan, K.W., et al. Long-term follow-up after reduced-intensity conditioning and stem cell transplantation for childhood nonmalignant disorders. Biol Blood Marrow Transplant 22 (2016), 1467–1472.
20. Dallas, M.H., Triplett, B., Shook, D.R., et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 19 (2013), 820–830.
21. Bolaños-Meade, J., Fuchs, E.J., Luznik, L., et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120 (2012), 4285–4291.
22. Oshrine, B.R., Olson, T.S., Bunin, N., Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease. Pediatr Blood Cancer 61 (2014), 1852–1859.
23. Marsh, R.A., Vaughn, G., Kim, M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 116 (2010), 5824–5831.
24. Shenoy, S., Eapen, M., Wu, J., et al. A multicenter phase II trial of unrelated donor reduced intensity bone marrow transplantation for children with severe sickle cell disease (SCURT): results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) study. 2015;126:619.
25. Locatelli, F., Kabbara, N., Ruggeri, A., et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 122 (2013), 1072–1078.
26. Eapen, M., Klein, J.P., Sanz, G.F., et al. Effect of donor-recipient HLA matching at HLA-A, -B, -C, and -DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 12 (2011), 1214–1221.
27. Koura, D.T., Horan, J.T., Langston, A.A., et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant 19 (2013), 1638–1649.
28. Saliba, R.M., Rezvani, K., Leen, A., et al. General and virus-specific immune cell reconstitution after double cord blood transplantation. Biol Blood Marrow Transplant 21 (2015), 1284–1290.
29. Shereck, E.B., Cooney, E., van de Ven, C., Della-Lotta, P., Cairo, M.S., A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 49 (2007), 306–312.
30. Bhatia, M., Jin, Z., Baker, C., et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 49 (2014), 913–920.
31. Leen, A.M., Bollard, C.M., Mendizabal, A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121 (2013), 5113–5123.
32. Melenhorst, J.J., Leen, A.M., Bollard, C.M., et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116 (2010), 4700–4702.
33. Parikh, S.H., Brochstein, J., Martin, P.L., et al. Successful engraftment of donor umbilical cord blood (UCB) cells after co-transplantation of Nicord® (ex vivo expanded UCB progenitor cells with nicotinamide) and a second unmanipulated cord blood unit after myeloablative chemotherapy in pediatric patients with severe sickle cell disease. Blood, 128, 2016, 3651.
34. Gragert, L., Eapen, M., Williams, E., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371 (2014), 339–348.
35. Horwitz, M.E., Chao, N.J., Rizzieri, D.A., et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 124 (2014), 3121–3128.